Navigation Links
Aratana Therapeutics Reports Second Quarter 2013 Financial Results
Date:8/12/2013

KANSAS CITY, Kan. and BOSTON, Aug. 12, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX) today announced its financial results for the second quarter of 2013, product development updates and the continued build-out of its pipeline.

For the quarter ended June 30, 2013, the Company reported a net loss of $4.2 million, or $(4.62) per share, compared with a net loss of $3.1 million, or $(10.21) per share for the quarter ended June 30, 2012. For the six months ended June 30, 2013, the Company reported a net loss of $8.3 million, or $(9.35) per share, compared with a net loss of $5.8 million, or $(19.15) per share for the six months ended June 30, 2012.

As of June 30, 2013, the Company had a total of approximately $20.2 million in cash, cash equivalents and marketable securities.
This number reflects the prepayment in June of $2.7 million of expenses related to the Company's initial public offering. In July, the Company completed the initial public offering which, together with the exercise of the underwriters' overallotment, provided $34.2 million in net proceeds. The Company's total cash and cash equivalents post-IPO was approximately $57.1 million.

"We are aggressively moving forward following our recent IPO with a sharp focus on our clinical programs and expanding our product pipeline," said Dr. Steven St. Peter, President and CEO of Aratana Therapeutics.  "We are pleased to share details on our progress and plans for the future."

Development Programs and Upcoming Milestones

  • AT-001 Dog: Completed enrollment in dose-ranging field study; results expected in November 2013; anticipate U.S. approval in 2016
  • AT-001 Cat: Anticipate initiating additional proof of concept study this month; results expected in November 2013
  • AT-002 Dog: Continuing discussion with the Center for Veterinary Medicine (CVM) to gain concur
    '/>"/>

  • SOURCE Aratana Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Aratana to Participate in Leerink Swanns November Management Access Days
    2. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
    3. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
    4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
    5. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
    6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
    7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... subscriptions from institutional and accredited investors for a ... of common stock and 3.35 million common stock ...
    (Date:7/27/2015)... 27, 2015 Bloomage BioTechnology Corporation Limited ("Bloomage" ... cooperation with the South Korean BioTech Company Medytox Inc. ... Medybloom to develop and promote Type A Botulinum Toxin ... Medytox, the Botulinum Toxin brand, occupies ... the fourth company in the world successfully developed and ...
    (Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
    Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3
    ... BEVERLY, Mass., March 8, 2011 Cellceutix Corporation (Pink ... has entered into a Confidential Disclosure Agreement (CDA) pertaining ... world,s largest pharmaceutical companies. Cellceutix CEO, ... to be signing a CDA on a compound before ...
    ... Inc. (Nasdaq: CPIX ), a specialty pharmaceutical ... announced fourth quarter and full year 2010 financial results. ... December 31, 2010, net revenue was $12.8 million, up 20% ... quarterly revenue growth was largely driven by 16% year-over-year growth ...
    Cached Medicine Technology:Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
    (Date:7/28/2015)... ... July 28, 2015 , ... ... has authorized the Company, from time to time and depending on market conditions, ... up to $25 million. Repurchases will be made in open market or privately ...
    (Date:7/28/2015)... , ... July 28, 2015 , ... ... more common in shipbreaking workers than they are in the general population. Surviving ... to read it now. , Researchers at Taiwan’s National Health Research Institutes ...
    (Date:7/28/2015)... ... July 28, 2015 , ... ... a proprietary, web based clinical knowledge system, called “Referral Guidance.” , ... It provides physicians who are anticipating making a subspecialty referral an efficient means ...
    (Date:7/28/2015)... ... , ... Women fear developing Alzheimer's disease more than having a heart attack ... are treatable, but there is little an individual can do to arrest the progress ... clinical trial, reports the July 2015 Harvard Women's Health Watch . , "There ...
    (Date:7/28/2015)... ... July 28, 2015 , ... Fertility specialist Dr. Lisa ... Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty ... esteemed colleagues and peers in the metro area as one of the most respected ...
    Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3
    ... Cancer is a common condition in India where beetle and ... found that certain bacteria’s excessive presence may give an early ... report published in the Open Access journal, Journal of Translational ... called squamous cell carcinoma) have six common species of ...
    ... affects young women and the condition// can sometimes be fatal. ... in the basal ganglia region of the brain. ,People ... and are unaware of the seriousness of their condition.When you ... the famous talented singer Karen Carpenter who died in the ...
    ... Oxidized phospholipids can be tested in blood to indicate the ... ,A report in the 7th July issue of New England ... phospholipids may indicate the amount of fatty build- up ... future be able to avoid the use of invasive ...
    ... British Columbia had showed that noise// might be not a ... so when that is effectively used to help the older ... the one sensation that comes in our way of concentration ... related to the disturbances that cause distractions in hearing something. ...
    ... role of fats, had been debated for a long// time. ... the between the various kinds of fats that are heart ... by banishing one kind of fat totally and taking only ... can help achieve the best possible diet for reducing cholesterol ...
    ... In a major breakthrough in the advancement of ... scan rare genetic mutation at a fraction of ... array diagonal gel electrophoresis. ,The technology devised ... in collaboration with Bristol, University college London, British ...
    Cached Medicine News:Health News:PET Scan find the Area of Brain Responsible for Anorexia Nervosa 2Health News:PET Scan find the Area of Brain Responsible for Anorexia Nervosa 3
    Sleek, all-metal head with large-diameter viewing window. 3X magnification....
    Provides 30% more magnification and twice the field of view. Adjustable focus....
    ... FSE are a new series of cryostats ... outside of the cryochamber, which allows easy ... temperature adjustment. Simple, multi-lingual touch-screen display for ... the main touch-screen display. Angle of clamp ...
    ... Spectra photocoagulator delivers power and reliability ... (DPSS) technology. Diode side-pumping technology drives ... compact Novus Spectra system, and active ... output and system reliability from your ...
    Medicine Products: